Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2013; 19(45): 8269-8281
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8269
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8269
Table 1 Demographic and clinical features of Crohn’s disease patients n (%)
| Characteristics | A series (n = 20) | B series (n = 14) |
| Sex | ||
| Male | 12 | 6 |
| Female | 8 | 8 |
| Age (yr) | ||
| Median (range) | 41 (25-61) | 40 (21-68) |
| BMI (kg/m2) | ||
| Median (range) | 25.5 (20-30) | 20.7 (17.2-21.9) |
| Disease duration (mo) | ||
| Median (range) | 75 (1-485) | 64 (24-360) |
| Disease location1 | ||
| L1 | 14 | 5 |
| L2 | 1 | 2 |
| L3 | 4 | 7 |
| L4 | None | None |
| L1-L4 | 1 | None |
| Disease behavior1 | ||
| B1 | None | 6 |
| B2 | 11 | 2 |
| B2-B3 | 8 | 6 |
| B3 | 1 | None |
| CDAI | ||
| Median (range) | 250 (151-537) | 244 (141-296) |
| Current therapies | ||
| Patients n | ||
| Mesalazine | 8 (40) | 3 (21.43) |
| Steroids | 2 (10) | 3 (21.43) |
| IS | 3 (15) | 3 (21.43) |
| IS + mesalazine | 1 (5) | 2 (14.29) |
| Steroids + mesalazine | 1 (5) | 1 (7.14) |
| Infliximab | 4 (20) | 2 (14.29) |
| IS + infliximab | 1 (5) | 0 |
- Citation: Ciccocioppo R, Vanoli A, Klersy C, Imbesi V, Boccaccio V, Manca R, Betti E, Cangemi GC, Strada E, Besio R, Rossi A, Falcone C, Ardizzone S, Fociani P, Danelli P, Corazza GR. Role of the advanced glycation end products receptor in Crohn’s disease inflammation. World J Gastroenterol 2013; 19(45): 8269-8281
- URL: https://www.wjgnet.com/1007-9327/full/v19/i45/8269.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i45.8269